Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Steven Marvel

Pulmonary Disease Salem, OR Medical Doctor

NPI 1588771323 CMS profile 71543

801 Mission St Se, Salem, OR 97302

Open in the dashboard

General payments

$7,622

494 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Steven Marvel of Salem, OR is reported in the CMS Open Payments database as having received $7,622 across 494 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 75th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $22 1
2022 General $1,386 79
2021 General $2,407 148
2020 General $1,842 120
2019 General $1,965 146

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Steven Marvel
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Steven Marvel were reported at $0. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Steven Marvel Pulmonary Disease median Middle half National median
2019 $1,965 $377 $109–$1,340 $163
2020 $1,842 $230 $56–$907 $114
2021 $2,407 $269 $68–$1,072 $132
2022 $1,386 $390 $100–$1,457 $149
2023 $0 $419 $114–$1,659 $160
2024 $22 $476 $123–$1,818 $164
2025 $0 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. GlaxoSmithKline, LLC. $1,384 119 payments
  2. AstraZeneca Pharmaceuticals LP $1,229 79 payments
  3. United Therapeutics Corporation $742 32 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $537 30 payments
  5. Grifols USA, LLC $522 55 payments
  6. Genentech USA, Inc. $448 25 payments
  7. Actelion Pharmaceuticals US, Inc. $357 20 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $199 9 payments
  9. Mylan Specialty L.P. $195 12 payments
  10. Insmed, Inc. $195 15 payments
  11. Other $1,814 98 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $7,466 487 payments
  2. Education $156 7 payments
Products named General payments · program years 2019–2024
  1. NUCALA Respiratory $581 46 payments
  2. Prolastin-C Liquid $522 55 payments
  3. TYVASO $458 18 payments
  4. SYMBICORT $402 29 payments
  5. Xolair $401 21 payments
  6. NUCALA Immunology $339 34 payments
  7. UPTRAVI $317 18 payments
  8. TRELEGY ELLIPTA $307 25 payments
  9. Esbriet $287 16 payments
  10. BREZTRI $282 19 payments
  11. Other $4,419 249 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

494 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record